Kelun-Biotech's final OS analysis of Phase III OptiTROP-Lung04 shows sac-TMT extended median overall survival in lung cancer.

HUTCHMED's SAFFRON trial shows savolitinib plus osimertinib met its Phase III goal in lung cancer, and a US filing has been ...

Researchers built a shark-antibody toxin that kills ERα36 breast cancer cells and shrinks tumors in mice. Human efficacy is unproven. Read the study now.

Roche's sefaxersen met its Phase III IMAgINATION trial endpoint, cutting proteinuria 43.1% vs placebo in IgA nephropathy.

DYNASTY-Breast02 met its primary endpoint for trastuzumab pamirtecan in HER2-low breast cancer, but companies flag limited ...

Novartis' oral BTK inhibitor remibrutinib (Rhapsido) met its primary endpoint in Phase III REMODEL-1 and REMODEL-2 relapsing ...

Iza-bren doubled progression-free survival vs chemotherapy in EGFR-mutated NSCLC in the Phase III PANKU LUNG-01 study. Read the full trial results now.

BioNTech and Bristol-Myers Squibb report a 36.7% confirmed response rate for pumitamig in advanced NSCLC after immunotherapy. Read the Phase 2 details now.

First participant vaccinated in Tumaini, a Phase II/III trial testing Bundibugyo vaccine candidates in Bunia, DRC. Read the full story on the response now.

Tango Therapeutics (Nasdaq: TNGX) reported an 82% objective response rate (ORR) for vopimetostat plus daraxonrasib in previously treated... China-based Sichuan Kelun-Biotech Biopharmaceutical (HKEX: ...

Roche secures worldwide rights to Zymeworks' DLL3 trispecific ZW209 for SCLC and neuroendocrine tumors. Read the full deal ...

Pathos AI and Bristol Myers Squibb launch an Alzheimer's AI drug development collaboration, including a USD 55m Tempus data ...